Dr. Lal Path Labs Ltd.
All news and filings related to Dr. Lal Path Labs Ltd..
View all news & filings- Medium impact
Dr. Lal Path Labs Completes Acquisition of Stake in SN Genelab Private Limited on Oct 1, 2026
Dr. Lal Path Labs Ltd. has successfully completed the acquisition of a stake in SN Genelab Private Limited. The transaction was finalized on October 1, 2026, as per the terms of the agreement.
Read the summary - Medium impact
Dr Lal PathLabs completes 80% stake acquisition in Ghana's Sunshine Healthcare Limited
Dr. Lal PathLabs Limited has completed the acquisition of an 80% stake in Sunshine Healthcare Limited (SHL), Ghana. This makes SHL a step-down subsidiary of DLPL. The acquisition was completed in accordance with the agreement and Ghanaian provisions.
Read the summary - Medium impact
Dr. Lal Path Labs Board Meeting Nov 4 to Approve Q2 FY27 Results; Trading Window Closed Oct 1-Nov 6
Dr. Lal PathLabs board meeting scheduled for November 4, 2026, to approve unaudited standalone and consolidated financial results for Q2 FY27 ending September 30, 2026. Trading window to remain closed from October 1, 2026, to November 6, 2026.
Read the summary - Medium impact
Dr. Lal Path Labs to acquire 70% stake in SN Genelab for up to ₹168 Cr
Dr. Lal Path Labs will acquire 70% of SN Genelab for up to ₹168 Crores plus a ₹31.5 Crores earn-out. The acquisition aims to enhance genomics expertise and diagnostic services. SN Gene's FY26 turnover was ₹57.96 Crores. The deal is expected to close by November 30, 2026.
Read the summary - Medium impact
Dr. Lal Path Labs Acquires 70% Stake in SN Gene for ₹168 Cr + Earn-out
Dr. Lal Path Labs will acquire 70% of SN Genelab Private Limited for up to ₹168 Crores plus a ₹31.5 Crores earn-out. The acquisition aims to strengthen genomics expertise and expand diagnostic services. SN Gene reported FY26 revenue of ₹57.96 Crores. The deal is expected to close by November 30, 2026.
Read the summary - Low impact
Dr. Lal Path Labs: Notice to Shareholders on Unclaimed Equity Shares
Dr. Lal Path Labs is notifying shareholders about unclaimed equity shares from FY 2019-20 due for transfer to the IEPF. Individual notices have been sent, and details are on the company website. The announcement was published on September 4, 2026.
Read the summary - Low impact
Dr. Lal PathLabs Subsidiary Completes 30% Stake Subscription in Neuome Technologies
Dr. Lal PathLabs' wholly-owned subsidiary, Dr. Lal Ventures, has completed the subscription of a 30% stake in Neuome Technologies Private Limited on August 27, 2026. Neuome Technologies is now an associate of the company.
Read the summary - Medium impact
Dr. Lal Path Labs Incorporates Step-Down Subsidiary in Uzbekistan
Dr. Lal PathLabs Limited, through its wholly-owned subsidiary Dr Lal PathLabs FZCO, has incorporated a new step-down subsidiary, Dr Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan on August 19, 2026. The company will subscribe to 70% of its share capital to expand its diagnostic services presence.
Read the summary - High impact
Dr. Lal PathLabs Q1 FY27: Revenue up 19.1% to ₹798 Cr, Declares 50% Interim Dividend
Dr. Lal PathLabs reported Q1 FY27 revenue of ₹798 crore, up 19.1% YoY, its highest growth in 4 years. PAT increased 27.2% to ₹170 crore. The company declared a 50% interim dividend (₹5/share). Acquisitions include Sunshine Healthcare (Ghana) and Neuome Technologies. Management expects CGHS/ECHS price hike benefits for 2-3 quarters.
Read the summary - Low impact
Dr. Lal Path Labs: Independent Director Gurinder Singh Kalra Completes Tenure on July 26, 2026
Mr. Gurinder Singh Kalra has completed his tenure as an Independent Director for Dr. Lal Path Labs Ltd. His cessation is effective July 26, 2026, closing business hours. The company has filed the required disclosures.
Read the summary - Medium impact
Dr. Lal Path Labs' AGM: Shareholders Approve Financials, Dividend, and Director Re-appointments
Dr. Lal Path Labs held its 32nd AGM on July 25, 2026. Shareholders approved financial statements for FY26, a final dividend of ₹4 per share, and re-appointments of directors including Rahul Sharma, Arvind Lal, and Rajit Mehta. Remuneration structures for key management were also revised and approved.
Read the summary - Low impact
Dr. Lal Path Labs Ltd. holds 32nd AGM on July 25, 2026; dividend declared.
Dr. Lal Path Labs Ltd. held its 32nd AGM on July 25, 2026. The company declared a final dividend of ₹4 per share. Key re-appointments include (Hony) Brig Dr Arvind Lal and Mr. Rajit Mehta. E-voting results will be announced by July 28, 2026.
Read the summary - Low impact
Dr. Lal Path Labs Publishes Q1 FY27 Financial Results in Newspapers
Dr. Lal PathLabs Limited published its financial results for the quarter ended June 30, 2026. The advertisements appeared in the Financial Express and Jansatta on July 25, 2026, as per SEBI regulations.
Read the summary - Low impact
LALPATHLAB: Audio Recording of Q1 FY27 Earnings Conference Call Available
Dr. Lal PathLabs Limited has released the audio recording of its Q1 FY27 earnings conference call, held on July 24, 2026. The recording is available on the company's investor relations website.
Read the summary - High impact
Dr. Lal Path Labs Q1 FY27 Revenue Surges 19.1% to ₹798 Crore on Strong Volume Growth
Dr. Lal Path Labs reported Q1 FY27 revenue of ₹798 crore, up 19.1% YoY, the highest in four years. EBITDA rose 28.7% to ₹247 crore, and PAT increased 27.2% to ₹170 crore. Growth was driven by 10.7% sample volume and 8.2% patient volume increases. Management remains confident in sustainable and profitable growth.
Read the summary - High impact
Dr Lal PathLabs Q1 FY27 Revenue up 19.1% to ₹798 Cr; PAT at ₹170 Cr
Dr Lal PathLabs reported Q1 FY27 consolidated revenue of ₹798 crore, up 19.1%. PAT increased 27.2% to ₹170 crore. The company acquired 80% of Sunshine Healthcare Limited (Ghana) for up to GHS 45.6 million and 30% of Neuome Technologies for up to ₹3.5 crore. An interim dividend of ₹5 per share was declared.
Read the summary - High impact
Dr. Lal Path Labs approves Q1 FY27 results, declares interim dividend of ₹5/share, and plans strategic acquisitions.
Dr. Lal Path Labs declared interim dividend of ₹5/share for FY27. The company's Board approved Q1 FY27 un-audited financial results. Key subsidiaries approved acquisitions: Dr. Lal PathLabs FZCO in Sunshine Healthcare Limited (Ghana) and Dr. Lal Ventures in Neuome Technologies (India). Stock options were also granted.
Read the summary - High impact
Dr. Lal Path Labs approves interim dividend of ₹5, approves two acquisitions, and grants stock options.
Dr. Lal Path Labs approved Q1 FY27 results and declared an interim dividend of ₹5 per share with a record date of July 30, 2026. The company also approved granting 119,300 stock options. Subsidiaries approved acquisitions in Ghana's Sunshine Healthcare (up to ₹380 million for 80%) and India's Neuome Technologies (up to ₹35 million for 30%). Both acquisitions are expected to close by August 31, 2026.
Read the summary - High impact
Dr. Lal Path Labs Approves Q1 FY27 Results, ₹5/Share Interim Dividend & Acquisitions
Dr. Lal Path Labs approved Q1 FY27 results and declared an interim dividend of ₹5 per share, record date July 30, 2026. Subsidiaries approved acquisitions: Dr. Lal PathLabs FZCO to acquire stake in Sunshine Healthcare (Ghana) for up to ₹380 million, and Dr. Lal Ventures to acquire stake in Neuome Technologies (India) for up to ₹35 million. Both acquisitions expected by August 31, 2026. Also approved 119,300 stock options grant.
Read the summary - High impact
Dr. Lal Path Labs Approves Interim Dividend of ₹5/Share, Acquires Stakes in Ghana and India Companies
Dr. Lal Path Labs approved interim dividend of ₹5 per share, record date July 30, 2026. Board approved Q1 FY26 results with consolidated revenue at ₹7,977 million and standalone revenue at ₹7,644 million. Subsidiaries are acquiring stakes in Sunshine Healthcare Limited (Ghana) for up to ₹380 million and Neuome Technologies (India) for up to ₹35 million, with completion expected by August 31, 2026. 119,300 stock options were granted.
Read the summary - High impact
Dr. Lal Path Labs declares interim dividend of ₹5/share; approves two acquisitions
Dr. Lal Path Labs approved Q1 FY27 unaudited financial results. The company declared an interim dividend of ₹5 per share with a record date of July 30, 2026. Stock options were granted to employees. Subsidiaries approved acquisitions: 80% stake in Ghana's Sunshine Healthcare for up to ₹380 million and 30% in India's Neuome Technologies for up to ₹35 million. Both acquisitions expected by August 31, 2026.
Read the summary - Medium impact
Dr. Lal Path Labs Wins Income Tax Appeal, ESOP Expenses Deduction Allowed
Dr. Lal Path Labs received a favorable appellate order from the Income Tax Department on July 17, 2026. The company's appeal was allowed, permitting a deduction of ₹32.66 crore for ESOP expenses.
Read the summary - Low impact
Dr. Lal Path Labs to Host Q1 FY27 Earnings Conference Call on July 24, 2026
Dr. Lal PathLabs will host an investor conference call on July 24, 2026, at 5:30 PM IST to discuss Q1 FY27 results. The call will feature the Executive Chairman, CEO, and CFO. Participants can pre-register for dial-in details.
Read the summary - Low impact
Dr. Lal Path Labs Dispatches AGM Notice and FY26 Annual Report
Dr. Lal Path Labs has dispatched the Notice for its 32nd Annual General Meeting and the Annual Report for FY 2025-26 to its members. The intimation was published in newspapers on July 02, 2026, in compliance with SEBI regulations.
Read the summary - Low impact
Dr. Lal Path Labs schedules 32nd AGM for July 25, 2026, to discuss FY26 Annual Report
Dr. Lal Path Labs will hold its 32nd AGM on July 25, 2026, at 10:00 AM IST via VC/OAVM. The company is dispatching the Annual Report for FY 2025-26 electronically to registered members and providing web-links to others. The cut-off date for email registration was June 26, 2026.
Read the summary - Low impact
Dr. Lal Path Labs Submits BRSR Report for FY 2025-26
Dr. Lal PathLabs Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26, adhering to SEBI regulations. The report details the company's ESG initiatives, operational data, employee welfare, and commitment to sustainable practices. It underscores the company's focus on ethical conduct and transparency.
Read the summary - Low impact
Dr. Lal Path Labs Ltd. Announces 32nd Annual General Meeting on July 25, 2026
Dr. Lal Path Labs Ltd. will hold its 32nd Annual General Meeting on July 25, 2026. The meeting will be conducted via Video Conferencing/ Other Audio Visual Means.
Read the summary - Low impact
Dr. Lal Pathlabs Board Meeting on July 24 to Approve Q1 FY27 Results; Trading Window Closed
Dr. Lal Path Labs will hold a Board meeting on July 24, 2026, to approve un-audited financial results for the quarter ending June 30, 2026. The trading window for securities will be closed from July 1, 2026, to July 26, 2026.
Read the summary - Low impact
Dr. Lal Path Labs Incorporates Wholly Owned Subsidiary 'DR LAL PATHLABS FZCO' in Dubai
Dr. Lal Path Labs incorporated its wholly-owned subsidiary, DR LAL PATHLABS FZCO, in Dubai on June 12, 2026. The company invested AED 1,91,35,000 (approx. ₹43.5 crore) for 100% shareholding. The subsidiary will focus on diagnostics and allied activities.
Read the summary - Low impact
Dr. Lal Path Labs to Hold Investor Meeting on May 20, 2026
Dr. Lal Path Labs Ltd. will hold a virtual investor meeting on May 20, 2026, with Centrum Investor Conference. The meeting is for analyst and institutional investors. No Unpublished Price Sensitive Information will be disclosed.
Read the summary - High impact
Dr. Lal PathLabs Q4 FY26 Revenue at ₹703 Crore, Up 16.6%; FY26 Revenue ₹2,763 Crore
Dr. Lal PathLabs reported Q4 FY26 revenue of ₹703 crore (up 16.6%) and FY26 revenue of ₹2,763 crore (up 12.2%). EBITDA for FY26 was ₹752 crore. The company plans ₹100-₹120 crore capex in FY27. A final dividend of 40% was approved. The company expects early to mid-teens revenue growth in FY27.
Read the summary - Medium impact
Dr. Lal Path Labs Completes Acquisition of Shahbazkers Diagnostic Centre
Dr. Lal Path Labs Limited has completed the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL) on May 1, 2026. SDCPL is now a wholly-owned subsidiary of Dr. Lal Path Labs.
Read the summary - Low impact
Dr. Lal Path Labs Publishes Q4 FY26 Financial Results in Newspapers
Dr. Lal PathLabs Limited published its financial results for the quarter and fiscal year ended March 31, 2026. The results were advertised in Financial Express and Jansatta on May 1, 2026, adhering to SEBI regulations.
Read the summary - Low impact
Dr. Lal Path Labs Q4 FY26 Earnings Call Audio Recording Available
Dr. Lal PathLabs has made the audio recording of its Q4 and FY26 earnings conference call available on its website. The call was held on April 30, 2026, providing insights for investors and analysts.
Read the summary - Medium impact
Dr. Lal Path Labs Q4 FY26 Revenue up 16.6% to ₹703 Cr, PAT at ₹132 Cr
Dr. Lal Path Labs reported Q4 FY26 revenue of ₹703 crore, up 16.6% YoY. Full-year FY26 revenue increased by 12.2% to ₹2,763 crore. Q4 PAT stood at ₹132 crore. The company saw strong volume growth and expanded its network by adding 14 labs and over 1100 collection centers.
Read the summary - Medium impact
Dr. Lal PathLabs Q4 FY26 Revenue up 16.6% to ₹703 Cr, PAT at ₹132 Cr, declares 40% Dividend
Dr. Lal PathLabs reported Q4 FY26 consolidated revenue of ₹703 crore, up 16.6%. EBITDA grew 10.5% to a 26.6% margin. PAT was ₹132 crore (18.8% margin). A final dividend of 40% (₹4 per share) was declared. Cash and equivalents stood at ₹1,526 crore.
Read the summary - High impact
Dr. Lal Path Labs Approves Final Dividend, Acquires 100% Stake in SDCPL, and Incorporates Dubai Subsidiary
Dr. Lal Path Labs approved FY26 results and recommended a ₹4 final dividend. The company will acquire 100% of SDCPL and incorporate a Dubai subsidiary. (Hony) Brig. Dr. Arvind Lal and Mr. Rajit Mehta were re-appointed. The AGM is on July 25, 2026.
Read the summary - High impact
Dr. Lal Path Labs Approves Final Dividend, Acquires 100% Stake in SDCPL, and Plans Dubai Subsidiary
Dr. Lal Path Labs approved Q4 and FY26 results, recommending a final dividend of ₹4/share. The company will acquire 100% of Shahbazkers Diagnostic Centre and establish a subsidiary in Dubai. (Hony) Brig. Dr. Arvind Lal and Mr. Rajit Mehta were re-appointed to key roles. The AGM is on July 25, 2026.
Read the summary - High impact
Dr. Lal Path Labs Board Approves FY26 Results, Recommends Final Dividend, and Plans Acquisitions
Dr. Lal Path Labs approved FY26 results and recommended a final dividend of ₹4 per share. The company will acquire 100% stake in SDCPL and establish a subsidiary in Dubai. (Hony) Brig. Dr. Arvind Lal and Mr. Rajit Mehta were re-appointed as directors. The AGM is on July 25, 2026.
Read the summary - High impact
Dr. Lal Path Labs Board Approves Final Dividend, Acquisition, and New Subsidiary
Dr. Lal Path Labs approved Q4 FY26 results, recommended a final dividend of ₹4/share, and will acquire 100% of Shahbazkers Diagnostic Centre. A new subsidiary in Dubai is also planned. (Hony) Brig. Dr. Arvind Lal and Mr. Rajit Mehta were re-appointed to key roles. The AGM is on July 25, 2026.
Read the summary - High impact
Dr. Lal Path Labs Approves Final Dividend, Acquires Stake, and Expands Internationally
Dr. Lal Path Labs approved Q4 FY26 results, recommended a final dividend of ₹4/share. The company will acquire 100% of SDCPL and establish a subsidiary in Dubai. (Hony) Brig. Dr. Arvind Lal and Mr. Rajit Mehta were re-appointed as directors. The AGM is on July 25, 2026.
Read the summary - High impact
Dr. Lal Path Labs Approves Final Dividend, Strategic Acquisitions, and Director Re-appointments
Dr. Lal Path Labs approved audited financial results for FY26, recommending a final dividend of ₹4 per share with a record date of June 26, 2026. The company will acquire 100% of Shahbazkers Diagnostic Centre and establish a Dubai subsidiary. (Hony) Brig. Dr. Arvind Lal was re-appointed Executive Chairman, and Mr. Rajit Mehta as Independent Director.
Read the summary - High impact
Dr. Lal Path Labs Board Approves FY26 Audited Results, Recommends Final Dividend, and Plans Acquisitions
Dr. Lal Path Labs approved audited FY26 results and recommended a final dividend of ₹4 per share. The company will acquire 100% of Shahbazkers Diagnostic Centre and establish a subsidiary in Dubai. (Hony) Brig. Dr. Arvind Lal and Mr. Rajit Mehta were re-appointed to the board. The AGM is on July 25, 2026.
Read the summary - Medium impact
Dr. Lal Path Labs Approves Final Dividend of ₹4/Share, Acquires 100% Stake in SDCPL
Dr. Lal Path Labs approved a final dividend of ₹4 per share for FY26. The company will acquire 100% of Shahbazkers Diagnostic Centre Private Limited and incorporate a subsidiary in Dubai. Key directors (Dr. Arvind Lal, Mr. Rajit Mehta) were re-appointed. The AGM is scheduled for July 25, 2026.
Read the summary - High impact
Dr. Lal Path Labs approves final dividend of ₹4, acquires 100% stake, and plans Dubai subsidiary.
Dr. Lal Path Labs approved audited results for FY26. A final dividend of ₹4 per share was recommended. The company will acquire 100% of Shahbazkers Diagnostic Centre and establish a Dubai subsidiary. (Hony) Brig. Dr. Arvind Lal and Mr. Rajit Mehta were re-appointed. The AGM is scheduled for July 25, 2026.
Read the summary - Low impact
Dr. Lal PathLabs to Host Q4 & FY26 Earnings Conference Call on April 30, 2026
Dr. Lal PathLabs Ltd. will host an investor and analyst conference call on April 30, 2026, at 5:30 PM IST to discuss Q4 and FY26 financial and operating performance. Key management personnel will be present. Pre-registration is available for participants.
Read the summary - Low impact
Dr. Lal Path Labs Files SEBI Compliance Certificate for Q4FY26
Dr. Lal Path Labs Ltd. submitted a compliance certificate for Q4FY26 from its RTA, MUFG Intime India Private Limited. The certificate confirms adherence to SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.
Read the summary - Low impact
Dr. Lal Path Labs Board Meeting on Apr 30 to Approve Q4 FY26 Audited Results; Trading Window Closed
Dr. Lal Path Labs will hold a board meeting on April 30, 2026, to approve audited financial results for Q4 FY26. The trading window will be closed from April 1, 2026, to May 2, 2026.
Read the summary - Medium impact
Dr. Lal Path Labs' Issuer Rating Upgraded to CARE AA+; Stable by CARE Ratings
Dr. Lal Path Labs Ltd.'s Issuer Rating upgraded by CARE Ratings from CARE AA; Stable to CARE AA+; Stable. The upgrade is based on the company's operational and financial performance for FY25 (audited) and 9MFY26 (unaudited). The rating action was communicated on March 25, 2026.
Read the summary - Low impact
Dr. Lal Path Labs publishes notice for unclaimed equity shares for FY 2018-19
Dr. Lal Path Labs Ltd. is issuing a notice to equity shareholders regarding unclaimed shares from FY 2018-19, which are to be transferred to the IEPF. Individual notices have been sent, and details are on the company's website. The advertisement was published on March 19, 2026.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio